Portal de Periódicos da CAPES

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

1999; Elsevier BV; Volume: 9; Issue: 13 Linguagem: Inglês

10.1016/s0960-894x(99)00288-7

1464-3405

Petpiboon Prasit, Z Wang, Christine Brideau, Chi‐Chung Chan, S. Charleson, Wanda Cromlish, Diane Ethier, Jilly F. Evans, A W Ford‐Hutchinson, J. Y. GAUTHIER, Robert J. Gordon, Jocelyne Guay, Michael J. Gresser, Stacia Kargman, Brian P. Kennedy, Y. LEBLANC, Serge Léger, Joseph A. Mancini, Gary P. O’Neill, Marc Ouellet, M. David Percival, H. Perrier, Denis Riendeau, Ian W. Rodger, Philip Tagari, Michel Thérien, Philip J. Vickers, Elizabeth Wong, Li-Jing Xu, Robert N. Young, Robert Zamboni, S. Boyce, N.M.J. Rupniak, M J Forrest, Denise M. Visco, D Patrick,

Synthesis of β-Lactam Compounds

The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx®) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.